FOXD3 and breast carcinoma: In addition, FOXD3-AS1 has been reported to enhance tamoxifen (TMX) resistance in breast cancer T47D and MCF7 cells through the microRNA-363/TFF1/PI3K/Akt signaling pathway (29).